Clinical trial NCT01850238: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Official title: A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability & Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Keywords: Alzheimer disease
tau protein
neurofibrillary degeneration
disease-modifying
Lead sponsor: Axon Neuroscience SE
Sponsor class: INDUSTRY
First posted: 2013-05-09
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.

AADvac1 is a vaccine directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs), and is intended to be a disease-modifying treatment for Alzheimer's disease, i.e. to halt its progress.

As this study is a Phase I study focused on tolerability and safety, efficacy will be assessed in an exploratory manner.

Detailed description: AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology. Based on preclinical results, the intervention is expected to reduce the number of neurofibrillary tangles, remove hyperphosphorylated tau protein and reduce the amount of oligomerized and insoluble pathological tau in the brain, to halt the spread of neurofibrillary pathology through the brain, and thus prevent associated cognitive decline.

The vaccine's antigenic determinant is a synthetic peptide derived from a tau protein sequence, which is coupled to keyhole limpet hemocyanin (KLH) and uses aluminum hydroxide (Alhydrogel) as an adjuvant.

At present AADvac1 is intended as an active immunotherapy for patients with diagnosed Alzheimer's disease (AD). Patients will receive 3 - 6 immunization doses; the raised titers of therapeutic antibodies and possible benefits of the treatment can extend beyond the duration of the study.

Because of the central role of pathological misfolded tau protein in the etiology of AD, the vaccine is expected to be more effective than active or passive immunotherapies aiming to eliminate the amyloid β plaques that have been clinically investigated so far.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria.
2. MMSE 15-26.
3. stable dose of Alzheimer's Disease treatment since 3 months before screening visit or being untreated.
4. Hachinski Ischemia Scale ≤ 4.
5. MRI consistent with the diagnosis of AD.
6. Informed consent capability
7. Written informed consent signed and dated by the patient \& caregiver.
8. Age between 50 and 85 years.
9. Availability of partner/caregiver.
10. Adequate visual and auditory abilities and German language skills for neuropsychological testing.
11. Females either surgically sterile or 2+ years postmenopausal.
12. Participant on stable doses of all medications for concomitant illnesses according to medical history for at least 30 days prior to Visit 1 if considered relevant by the investigator.
13. Sexually active males must be using reliable contraception methods or be surgically sterile.

Exclusion Criteria:

1. Pregnant women.
2. Participation in another clinical trial within 3 months before Visit 1.
3. Patients not expected to complete the clinical trial.
4. Presence or history of allergy to components of the vaccine, if considered relevant by the investigator.
5. Contraindication for MRI imaging (e.g. metallic endoprosthesis, stent implantation in the last 6 months).
6. Any of the following detected by brain MRI:

   * Thromboembolic infarction
   * Other focal lesions which may be responsible for the cognitive status of the patient
   * More than one lacunar infarct with a diameter of less than 1.5 cm in any dimension
   * Any lacunar infarct in a strategically important location such as the thalamus, hippocampus of either hemisphere, head of the left caudate
   * White matter lesions involving more than 25% of the hemispheric white matter
7. Surgery (under general anaesthesia) within 3 months prior to study entry and scheduled surgery during the whole study period.
8. History and/or presence of autoimmune disease, if considered relevant by the investigator.
9. Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia).
10. Active infectious disease (e.g., Hepatitis B, C).
11. Presence and/or history of Immunodeficiency (e.g., HIV).
12. Significant systemic illness, if considered relevant by the investigator.
13. Hypothyroidism (patients with corrected hypothyroidism are eligible for the study if treatment has been stable for 3 months before study entry)
14. History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or major depression.
15. Current depressive episode (Geriatric Depression Scale GDS \>5 at Visit 1).
16. Metabolic or toxic encephalopathy or dementia due to a general medical condition.
17. Alcoholism or substance abuse within the past year (alcohol or drug intoxication).
18. Wernicke's encephalopathy
19. History or evidence of any other CNS disorder that could be the cause of dementia (infectious or inflammatory/demyelinating CNS conditions, Creutzfeldt-Jakob disease, Parkinson's disease, Huntington's disease, brain tumour, subdural haematoma, etc.)
20. History or evidence of cerebrovascular disease (ischemic or haemorrhagic stroke, transient ischemic attack), or diagnosis of possible, probable or definite vascular dementia.
21. Epilepsy.
22. Prior and/or current treatment with experimental immunotherapeutics including IVIG or any vaccines for AD.
23. Current treatment with immunosuppressive drugs.
24. Change in dose of standard treatments for AD or hypothyroidism within 3 months prior to visit 1.
25. Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history within the last 30 days prior to visit 1, if considered clinically relevant by the investigator.

Primary outcomes:
measure: Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
timeFrame: Tolerability & safety are assessed over a period of 3 months / 3 administrations
Secondary outcomes:
measure: Immunogenicity of AADvac1
timeFrame: Immune response to the vaccine will be assessed over 3 months / 3 administrations
Other outcomes:
measure: Patient cognition
timeFrame: 3 months / 3 administrations, with an optional 3 months open label extension phase (3+3 administrations)
Locations:
city: Graz
country: Austria
facility: Medizinische Universitat Graz
state: Steiermark
city: Salzburg
country: Austria
facility: Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
city: Wien
country: Austria
facility: Medizinische Universitat Wien
Study officials:
affiliation: Medizinische Universität Graz
name: Reinhold Schmidt, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Zilka N, Winblad B, Novak M. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018 Oct 24;10(1):108. doi: 10.1186/s13195-018-0436-1.
citation: Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.
citation: Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014 Aug 1;6(4):44. doi: 10.1186/alzrt278. eCollection 2014.